Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on Conmed, Lowers Price Target to $150

Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and lowers the price target from $158 to $150.

byBenzinga Newsdesk

January 21, 2022

1 minute read

Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and lowers the price target from $158 to $150.

Citigroup Maintains Buy on Yum Brands, Raises Price Target to $170

By Benzinga Newsdesk

Today, 9:24 AM

Citigroup analyst Jon Tower maintains Yum Brands (NYSE:YUM) with a Buy and raises the price target from $168 to $170.

YUM

Mizuho Maintains Neutral on Mid-America Apartment, Raises Price Target to $207

By Benzinga Newsdesk

Today, 9:24 AM

Mizuho analyst Haendel St. Juste maintains Mid-America Apartment (NYSE:MAA) with a Neutral and raises the price target from $175 to $207.

MAA

Morgan Stanley Maintains Overweight on HubSpot, Raises Price Target to $796

By Benzinga Newsdesk

Today, 9:24 AM

Morgan Stanley analyst Stan Zlotsky maintains HubSpot (NYSE:HUBS) with a Overweight and raises the price target from $725 to $796.

HUBS

Notable Sprout Social Insider Trades $2.3M In Company Stock

By Benzinga Insights

Today, 9:24 AM

Justyn R. Howard, Chairman And CEO at Sprout Social (NASDAQ:SPT), made a large buy and sell of company shares on October 8, according to a new SEC filing.

SPT

Needham Maintains Buy on Conmed, Lowers Price Target to $150

Related Posts

Citigroup Maintains Buy on Yum Brands, Raises Price Target to $170

Mizuho Maintains Neutral on Mid-America Apartment, Raises Price Target to $207

Morgan Stanley Maintains Overweight on HubSpot, Raises Price Target to $796

Notable Sprout Social Insider Trades $2.3M In Company Stock